Recipient vascular endothelial growth factor serum levels predict primary lung graft dysfunction

American Journal of Transplantation

Volumn 7, Issue 3, 2007, Pages 700-706

  Krenn, K ^a,b   Klepetko, W ^b   Taghavi, S ^b   Lang, G ^b   Schneider, B ^b   Aharinejad, S ^a,b  

^a Medical University of Vienna   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Lung transplantation; Primary graft dysfunction; Serum marker; VEGF

Indexed keywords

BIOLOGICAL MARKER; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD VESSEL PERMEABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HEART MUSCLE ISCHEMIA; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG GRAFT DYSFUNCTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; OXYGEN TENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY;

ADULT; DELAYED GRAFT FUNCTION; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; PROGNOSIS; RISK; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847735943     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01673.x     Document Type: Article

References (33)

1. Patterson GA. Results of bilateral lung transplantation. In: Patterson GA, Couraud L, eds. Current topics in general thoracic surgery, Vol 3: Lung transplantation. Amsterdam, Netherlands: Elsevier, 1995: 363-378.
2. Arcasoy SM, Kotloff RM. Lung transplantation. N Engl J Med 1999; 340: 1081-1091.
3. Hosenpud JD, Bennet LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: Sixteenth official report, 1999. J Heart Lung Transplant 1999; 18: 611-626.
4. Christie JD, Kotloff RM, Ahya VN et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005; 171: 1312-1316.
5. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: Definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24: 1454-1459.
6. Dahlberg PS, Prekker ME, Herrington CS, Hertz MI, Park SJ. Medium-term results of extracorporeal membrane oxygenation for severe acute lung injury after lung transplantation. J Heart Lung Transplant 2004; 23: 979-984.
7. Shargall Y, Guenther G, Ahya VN, Ardehali A, Singhal A, Keshavjee S. ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: Treatment. J Heart Lung Transplant 2005; 24: 1489-1500.
8. Christie JD, Bavaria JE, Palevsky HI et al. Primary graft failure following lung transplantation. Chest 1998; 114: 51-60.
9. de Perrot M, Bonser RS, Dark J et al. Report of the ISHLTWorking Group on Primary Lung Graft Dysfunction part III: Donor-related risk factors and markers. J Heart Lung Transplant 2005; 24: 1460-1467.
10. Barr ML, Kawut SM, Whelan TP et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: Recipient-related risk factors and markers. J Heart Lung Transplant 2005; 24: 1468-1482.
11. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
12. Abraham D, Taghavi S, Riml P et al. VEGF-A and -C but not -B mediate increased vascular permeability in preserved lung grafts. Transplantation 2002; 73: 1703-1706.
13. Aharinejad S, Taghavi S, Klepetko W, Abraham D. Prediction of lung-transplant rejection by hepatocyte growth factor. Lancet 2004; 363: 1503-1508.
14. Arcasoy SM, Fisher A, Hachem RR, Scavuzzo M,Ware LB. ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: Predictors and outcomes. J Heart Lung Transplant 2005; 24: 1483-1488.
15. Steinberg JB, Mao HZ, Niles SD, Jutila MA, Kapelanski DP. Survival in lung reperfusion injury is improved by an antibody that binds and inhibits L- and E-selectin. J Heart Lung Transplant 1994; 13: 306-318.
16. Eppinger MJ, Jones ML, Deeb GM, Bolling SF, Ward PA. Pattern of injury and the role of neutrophils in reperfusion injury of rat lung. J Surg Res 1995; 58: 713-718.
17. Naidu BV, Woolley SM, Farivar AS et al. Early tumor necrosis factor-alpha release from the pulmonary macrophage in lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2004; 127: 1502-1508.
18. Serrick C, Adoumie R, Giaid A, Shennib H. The early release of interleukin-2, tumor necrosis factor-alpha and interferon-gamma after ischemia reperfusion injury in the lung allograft. Transplantation 1994; 58: 1158-1162.
19. Schnickel GT, Ross DJ, Beygui R et al. Modified reperfusion in clinical lung transplantation: The result of 100 consecutive cases. J Thorac Cardiovasc Surg 2006; 131: 218-223.
20. Tai MH, Kuo SM, Liang HT et al. Modulation of angiogenic processes in cultured endothelial cells by low density lipoproteins subfractions from patients with familial hypercholesterolemia. Atherosclerosis 2006; 186: 448-457.
21. Itaya H, Imaizumi T, Yoshida H, Koyama M, Suzuki S, Satoh K. Expression of vascular endothelial growth factor in human monocyte/macrophages stimulated with lipopolysaccharide. Thromb Haemost 2001; 85: 171-176.
22. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211-220.
23. Webb NJ, Myers CR, Watson CJ, Bottomley MJ, Brenchley PE. Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine 1998; 10: 254-257.
24. Godzich M, Hodnett M, Frank JA et al. Activation of the stress protein response prevents the development of pulmonary edema by inhibiting VEGF cell signaling in a model of lung ischemia-reperfusion injury in rats. FASEB J 2006; 20: 1519-1521.
25. McColley SA, Stellmach V, Boas SR, Jain M, Crawford SE. Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation. Am J Respir Crit Care Med 2000; 161: 1877-1880.
26. Benisty JI, McLaughlin VV, Landzberg MJ, et al. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest 2004; 126: 1255-1261.
27. Eddahibi S, Humbert M, Sediame S et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respir Crit Care Med 2000; 162: 1493-1499.
28. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 2006; 290: L209-L221.
29. Weiss TW, Mehrabi MR, Kaun C et al. Prostaglandin E1 induces vascular endothelial growth factor-1 in human adult cardiac myocytes but not in human adult cardiac fibroblasts via a cAMP-dependent mechanism. J Mol Cell Cardiol 2004; 36: 539-546.
30. Iglarz M, Silvestre JS, Duriez M, Henrion D, Levy BI. Chronic blockade of endothelin receptors improves ischemia-induced angiogenesis in rat hindlimbs through activation of vascular endothelial growth factor-NO pathway. Arterioscler Thromb Vasc Biol 2001; 21: 1598-1603.
31. Granger DN, Perry MA. Permeability characteristics of the microcirculation. In: Mortillaro NA, ed. The physiology and pharmacology of the microcirculation, Vol. 1. New York, NY: Academic Press 1983: 157-208.
32. Kaner RJ, Ladetto JV, Singh R, Fukuda N, Matthay MA, Crystal RG. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol 2000; 22: 657-664.
33. Le Cras TD, Spitzmiller RE, Albertine KH, Greenberg JM, Whitsett JA, Akeson AL. VEGF causes pulmonary hemorrhage, hemosiderosis, and air space enlargement in neonatal mice. Am J Physiol Lung Cell Mol Physiol 2004; 287: L134-L142.